Farias Alessandro S, Santos Leonilda M B
Neuroimmunomodulation Group and Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas, Campinas, São Paulo, Brazil.
Proteomics Clin Appl. 2015 Oct;9(9-10):844-7. doi: 10.1002/prca.201400171. Epub 2015 Jul 24.
Multiple sclerosis affects more than 2.5 million people worldwide. Although multiple sclerosis was described almost 150 years ago, there are many knowledge gaps regarding its etiology, diagnosis, prognosis, and pathogenesis. Multiple sclerosis is an inflammatory, demyelinating, neurodegenerative disease of the CNS. During the last several decades, experimental models of multiple sclerosis have contributed to our understanding of the inflammatory disease mechanisms and have aided drug testing and development. However, little is known about the neurodegenerative mechanisms that operate during the evolution of the disease. Currently, all therapeutic approaches are primarily based on the inflammatory aspect of the disease. During the last decade, proteomics has emerged as a promising tool for revealing molecular pathways as well as identifying and quantifying differentially expressed proteins. Therefore, proteomics may be used for the discovery of biomarkers, potential drug targets, and new regulatory mechanisms. To date, a considerable number of proteomics studies have been conducted on samples from experimental models and patients with multiple sclerosis. These data form a solid base for further careful analysis and validation.
多发性硬化症影响着全球超过250万人。尽管多发性硬化症在近150年前就已被描述，但在其病因、诊断、预后和发病机制方面仍存在许多知识空白。多发性硬化症是一种中枢神经系统的炎症性、脱髓鞘性神经退行性疾病。在过去几十年里，多发性硬化症的实验模型有助于我们理解炎症性疾病机制，并辅助了药物测试和开发。然而，对于疾病发展过程中起作用的神经退行性机制却知之甚少。目前，所有治疗方法主要基于该疾病的炎症方面。在过去十年中，蛋白质组学已成为一种有前景的工具，可用于揭示分子途径以及识别和定量差异表达的蛋白质。因此，蛋白质组学可用于发现生物标志物、潜在药物靶点和新的调节机制。迄今为止，已经对来自实验模型和多发性硬化症患者的样本进行了大量蛋白质组学研究。这些数据为进一步的仔细分析和验证奠定了坚实基础。
